Jon Mcclelland Lockard

Array ( [id] => 17577000 [patent_doc_number] => 20220133855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/578147 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17578147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003573 [patent_doc_number] => 20220362339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/576886 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563218 [patent_doc_number] => 20220127367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/570248 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988891 [patent_doc_number] => 20220354928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => METHODS AND COMPOSITIONS OF NEUREGULINS FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE [patent_app_type] => utility [patent_app_number] => 17/558451 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657102 [patent_doc_number] => 20220177567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => ANTI-IL12RB1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/546801 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593655 [patent_doc_number] => 20220143228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS [patent_app_type] => utility [patent_app_number] => 17/532919 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17726590 [patent_doc_number] => 11382955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Long-acting VEGF inhibitors for intraocular neovascularization [patent_app_type] => utility [patent_app_number] => 17/526929 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 24 [patent_no_of_words] => 16047 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17526929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368327 [patent_doc_number] => 12060397 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Soluble lipidated ligand agents for treating eye inflammation [patent_app_type] => utility [patent_app_number] => 17/525169 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 42735 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718894 [patent_doc_number] => 20220211613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => EXTENDED RELEASE OF NEUREGULIN FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/510271 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17510271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657112 [patent_doc_number] => 20220177577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/508759 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923008 [patent_doc_number] => 20240026012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => BINDERS AND CHIMERIC ANTIGEN RECEPTORS WHICH SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 4 [patent_app_type] => utility [patent_app_number] => 18/027305 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39242 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355414 [patent_doc_number] => 20220016210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => AFLIBERCEPT FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/492649 [patent_app_country] => US [patent_app_date] => 2021-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17492649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806941 [patent_doc_number] => 20230381274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => TIGHT JUNCTION (ZONULAE OCCLUDENTES) PROTEIN FOR USE IN TREATING OR PREVENTING EPILEPSY [patent_app_type] => utility [patent_app_number] => 18/028240 [patent_app_country] => US [patent_app_date] => 2021-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790567 [patent_doc_number] => 20220249658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Methods Of Treatment Of Keloid Using An Anti-VEGF Agent [patent_app_type] => utility [patent_app_number] => 17/485067 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17485067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314513 [patent_doc_number] => 20210403561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ANTI-TREM-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/472302 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336073 [patent_doc_number] => 20220002404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => ANTI-TREM-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/472051 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18108072 [patent_doc_number] => 20230000952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/459556 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343700 [patent_doc_number] => 20220010031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/408768 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17408768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274453 [patent_doc_number] => 20210380651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => COMPOSITIONS FOR DISEASE TREATMENT [patent_app_type] => utility [patent_app_number] => 17/407111 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428403 [patent_doc_number] => 20220056111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF [patent_app_type] => utility [patent_app_number] => 17/399364 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 569 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399364 [rel_patent_id] =>[rel_patent_doc_number] =>)